Synairgen Plc said its drug helped reduce the risk of developing severe diseases
in hospitalized COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.
The trial, which used interferon beta, showed that patients who were given Synairgen’s formulation had a 79 percent
lower risk of developing severe disease compared to placebo.
Patients who received the drug, SNG001, were more than twice as likely to recover from COVID-19 as those on placebo,
the company said.